AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Jul 24, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-07-20

Reporting Person: Bowden Christopher (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-20	Performance share units	$	A	6265	Acquired		Common Stock (6265)	Direct

Footnotes

F1: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

F2: The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.